Investigative Sites Honor INC Research/inVentiv Health With 2017 Society For Clinical Research Sites Eagle Award

Prestigious Industry Award Recognizes Company’s Superior Leadership and Commitment to Site Collaborations to Advance Patient Health

RALEIGH, N.C. – October 9, 2017 – INC Research/inVentiv Health (Nasdaq:INCR), the only fully integrated biopharmaceutical solutions organization combining a CRO and CCO (Contract Commercial Organization), today announced that it was awarded the 2017 Society for Clinical Research Sites (SCRS) Eagle Award in the CRO category during the SCRS Annual Global Site Solutions Summit held October 6-8 in Boca Raton, Florida. The award recognizes the CRO that best exemplifies outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships.

“We’re honored to receive this award, which demonstrates the advances we’ve made collaborating with sites to streamline various aspects of the clinical trial process, such as investigator payments,” said Clare Grace, PhD, Vice President, Site and Patient Access, who accepted the award on behalf of INC Research/inVentiv Health during the Summit. “This award is only possible because of the valuable contributions of our sites and global team who’ve been dedicated to the continuous improvement of the clinical development experience. Together, we’re creating best-in-class site processes to optimize performance, reduce risk and speed the delivery of therapies to patients.”

"INC Research/inVentiv Health has a long history of commitment to the importance of site relationships," said Christine Pierre, President of SCRS. "It is rewarding to see them receive public recognition by the sites as the recipient of the Eagle Award, identifying them as a CRO of choice for sites to partner with."

To select this year’s finalists, SCRS members – nearly 9,000 research sites in 45 countries – were invited to nominate the CRO they believe best demonstrates a strong commitment to site partnership. Selection criteria included availability of qualified staff to support sites, willingness to collaborate, protocol design and execution, financial consideration and partnering with sites for future work. CROs that ranked in the 75th percentile or above in the initial round of voting were then moved to a final ballot. All sites, regardless of SCRS membership, were able to select a winner for announcement at the Summit.

Beyond the award win, INC Research/inVentiv Health’s continued commitment to sites was on display at the Summit with the company’s extensive participation in eight sessions. Experts from the end-to-end CRO and CCO led discussions on issues that impact the way sites do research and recruit patients, including topics ranging from how ICH updates will impact sites to justifying recruitment budgets. INC Research/inVentiv Health also hosted a Site Appreciation Reception to recognize and celebrate the vital role sites play in the clinical research process.

The Eagle win comes on the heels of INC Research/inVentiv Health being named CenterWatch’s “Top CRO to Work With” among the top 10 global CROs in the 2017 CenterWatch Global Investigative Site Relationship Survey. The Company is the only CRO to rank consistently among the top three CROs in all seven CenterWatch site relationship surveys conducted over the last decade.

To learn more about INC Research/inVentiv Health’s site and patient engagement programs, join the company’s online Catalyst Community for sites or to participate in current studies, please visit

About INC Research/inVentiv Health

INC Research/inVentiv Health (Nasdaq:INCR) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to address new market realities where clinical and commercial share expertise, data and insights to accelerate biopharmaceutical performance. With more than 22,000 employees and the ability to support customers in more than 110 countries, our global scale and deep therapeutic alignment enables INC Research/inVentiv Health to help customers successfully navigate an increasingly complex environment. For more information on our Raleigh, N.C.-based company, visit or

Investor Relations Contact:
Ronnie Speight
Vice President, Investor Relations
+1 919 745 2745

Press/Media Contact:
Danielle DeForge
Senior Director, External Communications
+1 781 425 2624

Back to news